Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT04975997 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT04975997
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04975997 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)
Lead sponsor
Celgene
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 23, 2022
Completion date
June 25, 2032
Enrollment
939 (actual)
Sites
259

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma